Today's Rundown SVB buys Leerink for $280M, boosting its life sciences business Preclinical biotech Synthorx wants a $100M IPO Eli Lilly files for FDA approval of migraine drug lasmiditan [Sponsored] Global Life Science Services Platform Unites Under New Name, EVERSANA Google to retake DeepMind’s AI healthcare unit, as it moves toward a cohesive strategy [Sponsored] Mining Real-World Data With Cutting-Edge Analytical Tools Bayer VP Alan Westwood to lead antimicrobial firm Matoke Pharma Celgene expands Dragonfly NK cells pact to the tune of $50M Featured Story | | | Wednesday, November 14, 2018 Silicon Valley Bank parent SVB is buying Leerink to create a new company with a "complete capital markets offering." |
|
|
| This week's sponsor is United for Medical Research. | | | |
Top Stories Wednesday, November 14, 2018 Moderna will be getting all the headlines for its monster $500 million IPO attempt this week, but that shouldn’t overshadow the major $100 million IPO that early-stage Synthorx has just announced, and what this says about the biotech market. Wednesday, November 14, 2018 Eli Lilly has filed for FDA approval of migraine drug lasmiditan. The Big Pharma is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug clears headache pain in two hours in some patients. Monday, November 12, 2018 EVERSANA delivers a fully-integrated service portfolio to help life science leaders create value for key constituents across the product lifecycle. Tuesday, November 13, 2018 Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business, including those behind its mobile app for doctors and nurses. Wednesday, November 14, 2018 In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream. Tuesday, November 13, 2018 Former Bayer VP Alan Westwood has taken the reins of British antimicrobial biotech Matoke Pharma. Wednesday, November 14, 2018 Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million upfront for access to four more natural killer (NK) cell-based programs. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Forte Research Systems Discover what over 800 of your peers think about technology's impact on clinical trial operations. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Compliance Training for Professionals working in APAC region March 4-7, 2019 | Singapore Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami | 